Tebentafusp improves OS: A First in Metastatic Uveal Melanoma

First-line tebentafusp significantly improved overall survival (OS) when compared with immunotherapy or chemotherapy in patients with metastatic uveal melanoma in a phase 3 trial.
Medscape Medical News